Antiobestic agents methods for screening antiobestic agents and kits comprising same
View Patent ↗The present invention provides a method for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, characterized by using MCH or its derivative or a salt thereof and SLC-1 or its salt is useful for screening an SLC-1 agonist which can be used not only as an appetite (eating) promoting agent but also as a prophylactic/therapeutic agent for weak pains, atonic bleeding, before and after expulsion, subinvolution of uterus, cesarean section, induced abortion, galactostasis, and the like, and an SLC-1 antagonist which can be used not only as an antiobestic agents (drug), an appetite (eating) modulator, and the like, but also as a prophylactic/therapeutic agent for hyperstimulation, ankylosing uterine contractions, fetal distress, uterine rupture, cervical laceration, preterm delivery, Prader-Wili syndrome and the like.
1. A method for screening a compound or its salt that alters the binding property between [ 125 I][N-(3-(4-hydroxy-3-iodophenyl)propionyl)-Met 4 ]-MCH(4-19) and SLC-1 or its salt, which comprises:
measuring the amount of the [ 125 I][N-(3-(4-hydroxy-3-iodophenyl)propionyl)- 4 Met 4 ]-MCH(4-19) bound to the SLC-1, (i) when the [ 125 I][N-(3-(4-hydroxy-3-iodophenyl)propionyl) 4 Met 4 ]-MCH(4-19) is brought into contact with the SLC-1 or a salt thereof, and (ii) when a test compound and the [ 125 I][N-(3-(4-hydroxy-3-iodophenyl)propionyl) 4 Met 4 ]-MCH(4-19) are brought into contact with the SLC-1 or a salt thereof; and
comparing (i) and (ii).
2. The method according to claim 1 , wherein the [ 125 I][N-(3-(4-hydroxy-3-iodophenyl)propionyl) 4 Met 4 ]-MCH(4-19) is represented by the following formula:
3. [ 125 I][N-(3-(4-hydroxy-3-iodophenyl)propionyl)- 4 Met 4 ]-MCH(4-19) which is represented by the following formula:
4. A kit for screening a compound or its salt that alters the binding property between [ 125 I][N-(3-(4-hydroxy-3-iodophenyl) 4 Met 4 ]-MCH(4-19) and SLC-1 or its salt, which comprises a solution comprising (a) [ 125 I][N-(3-(4-hydroxy-3-iodophenyl)propionyl) 4 Met 4 ]-MCH(4-19) and (b) a buffer.
5. The kit according to claim 4 , wherein the [ 125 I][N-(3-(4-hydroxy-3-iodophenyl)propionyl) 4 Met 4 ]-MCH(4-19) is represented by the following formula: